Next Article in Journal
Deoptimization of FMDV P1 Region Results in Robust Serotype-Independent Viral Attenuation
Next Article in Special Issue
Hepatitis C and Human Pegivirus Coinfection in Patients with Chronic Hepatitis C from the Brazilian Amazon Region: Prevalence, Genotypes and Clinical Data
Previous Article in Journal
Unique Profile of Proinflammatory Cytokines in Plasma of Drug-Naïve Individuals with Advanced HIV/TB Co-Infection
 
 
Article
Peer-Review Record

Donated Blood Screening for HIV, HCV and HBV by ID-NAT and the Residual Risk of Iatrogenic Transmission in a Tertiary Care Hospital Blood Bank in Puebla, Mexico

Viruses 2023, 15(6), 1331; https://doi.org/10.3390/v15061331
by Francisca Sosa-Jurado 1, Roxana Palencia-Lara 2, Cinthia Xicoténcatl-Grijalva 1, Maribel Bernal-Soto 2, Álvaro Montiel-Jarquin 3, Yolanda Ibarra-Pichardo 2, Nora Hilda Rosas-Murrieta 4, Rosalia Lira 5, Paulina Cortes-Hernandez 6 and Gerardo Santos-López 1,*
Reviewer 2:
Viruses 2023, 15(6), 1331; https://doi.org/10.3390/v15061331
Submission received: 11 May 2023 / Revised: 1 June 2023 / Accepted: 5 June 2023 / Published: 6 June 2023
(This article belongs to the Special Issue Viral Hepatitis in Latin America and the Caribbean)

Round 1

Reviewer 1 Report

Dear authors, I read your paper, and I found it very easy to read and interesting. Data are well presented, results and clear, and the discussion is appropriate, too. I suggest to accept the paper after few revision.

Main issue: please include in the discussion a "limits of the study" paragraph, including that it is a monocentre study and any other study limitations you can detect;

Minor issue: Just a question about HBV: despite you give an appropriate laboratory/methodological reason for increase of HBV, you said the a real increase of cases cannot be excluded. I suggest to integrate this point with some information about HBV vaccination policies and coverage in MExico. In most EU countries, HBV vaccination is mandatory since the mid 80ies of last century, so HBV is progressively disappearing. What about HBV vaccination in Mexico) 

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Reviewer 2 Report

This is a large cross-sectional study of blood-borne pathogens in blood donors across two distinct study periods in Puebla, Mexico.   Overall, the manuscript is well written, and the methodologies are appropriate and well described.  Minor revisions would strengthen the manuscript further including:

·      Inclusion criteria are mentioned in section 2.1 but should be stated explicitly.

·      How many individuals had more than infection diagnosed simultaneously?

·      Are there data to suggest subtype- or genotype-specific NAT detection rates for HIV, HBV or HCV?

·      The discussion should include currently HBV vaccination standards, as well as HIV, HBV, and HCV treatment options available in both the public and private sections (if different).

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Back to TopTop